CTOs on the Move

Cue Health

www.cuehealth.com

 
Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.cuehealth.com
  • 4980 Carroll Canyon Road Suite 100
    San Diego, CA USA 92121
  • Phone: 858.412.8151

Executives

Name Title Contact Details
Vimal Subramanian
 Chief Information Security Officer Profile
Vimal Subramanian
 Head of Information Security and Privacy Profile

Funding

Cue Health raised $13M on 04/01/2020
Cue Health raised $100M on 06/10/2020
Cue Health raised $481M on 10/14/2020
Cue Health raised $235M on 05/13/2021

Similar Companies

Clear Cycle

Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioBuzz

Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.

Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies.

BD Biosciences - Canada

BD Biosciences - Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.